Global Pharmaceuticals Industry Strategic Research Report 2026-2031

Publication ID:

NAV0826016

Publication Date:

August 21, 2026

Pages:

374

Countries:

Global

$4,500.00

Buying Frequently for your Organization?

Click here to know more about our subscription packages.

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

The global pharmaceutical consumption market was valued at approximately $1.55 trillion in calendar year 2024, advancing to an estimated $1.65 trillion in 2025, the report's base year. Over the 2025-2031 forecast window, the market is projected to expand at a compound annual growth rate of 6.8% in nominal US dollar terms, reaching $2.45 trillion by 2031 - an absolute increment of approximately $795 billion of annual consumption value across the period.

This forecast acceleration is material relative to the historical baseline. The 2022-2024 historical CAGR stood at 4.3%, a comparatively subdued rate reflecting post-COVID-19 normalisation of vaccine demand and inventory destocking. The transition to the 6.8% forward trajectory is underpinned by five discrete structural catalysts, the largest being GLP-1 receptor agonist and cardiometabolic franchise expansion (anchored by semaglutide and tirzepatide), estimated to add approximately $280 billion of incremental consumption value by 2031.

Twenty-five companies are profiled in depth, including Johnson & Johnson, Pfizer, Roche, Merck, AbbVie, Novartis, AstraZeneca, Sanofi, Bristol-Myers Squibb, Eli Lilly, GSK, Novo Nordisk, Takeda, Bayer, Boehringer Ingelheim, Amgen, Gilead, Vertex, Regeneron, Biogen, Moderna, Teva, Viatris, Sun Pharma, and Dr. Reddy's Laboratories.

Scope of Global Pharmaceuticals Industry Strategic Research Report 2026-2031

This report provides forecast data by value (in USD billion) till 2031 for the global pharmaceutical consumption (drug market) industry, with 2025 as the base year and 2022-2024 as the historical period.
This report provides segment by type (Small Molecule, Biologics, Vaccines, Cell and Gene Therapy, Peptide Therapeutics, Oligonucleotides, and Combination/OTC/Other) forecast data by value for the global pharmaceutical consumption market till 2031.
This report provides application segments (Oncology, Cardio-Metabolic, Immunology and Inflammation, Infectious Disease, Neurology and CNS, Respiratory, Rare Diseases and Orphan Drugs, and Other Applications) forecast data by value for the global pharmaceutical consumption market till 2031.
This report provides region-wise (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) forecast data by value for the global pharmaceutical consumption market till 2031.
This report also provides country-wise forecast data by value for the United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, Switzerland, Netherlands, Belgium, Turkey, and other major markets across all five regions.
This report identifies key growth drivers and inhibitors (pain points) affecting the global pharmaceutical consumption market.
This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis, company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and Strategic Implications, along with competitive landscape for 25 key companies in the global pharmaceutical consumption market.
This report provides Porter's Five Forces analysis for the global pharmaceutical consumption market.
This report provides PESTLE (political, economic, social, technological, legal and environmental) analysis for the global pharmaceutical consumption market.
This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis for the global pharmaceutical consumption market.
This report identifies key future trends in the global pharmaceutical consumption market.

Segment by Type in Global Pharmaceuticals Industry Market

Small Molecule (Chemical)
Biologics (mAbs, Recombinant Proteins)
Vaccines
Cell and Gene Therapy
Peptide Therapeutics
Oligonucleotides (siRNA and Antisense Oligonucleotides)
Combination, OTC and Other

Segment by Application in Global Pharmaceuticals Industry Market

Oncology
Cardio-Metabolic (Diabetes, Obesity, and Cardiovascular)
Immunology and Inflammation
Infectious Disease (Including Vaccines)
Neurology and Central Nervous System
Respiratory
Rare Diseases and Orphan Drugs
Other Applications

Segment by Region in Global Pharmaceuticals Industry Market

North America
- United States
- Canada
- Rest of North America
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Switzerland
- Netherlands
- Belgium
- Turkey
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of Middle East & Africa

Who can use the Global Pharmaceuticals Industry Market Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the global pharmaceutical consumption market. Some of the intended users for this report are:

C-level executives and Company Directors in pharmaceutical, biotechnology, and healthcare companies
Industry consultants and Management consultants
Marketing professionals and Business development professionals
Investment managers, Financial professionals, and Venture Capitalists
Bank Managers, M&A Managers, and Auditors
Payers, Healthcare Policy Analysts, and Market Access professionals
Portfolio Managers and Equity Research Analysts covering pharmaceuticals
Anyone operating in the pharmaceutical industry value chain, from R&D through commercialization

Table of Contents

Executive Summary
1. 1.1 Market Scope and Research Methodology
2. 1.2 Headline Market Valuation and Forecast Trajectory
3. 1.3 Structural Growth Drivers
4. 1.4 Regional and Country-Level Analysis
5. 1.5 Competitive Landscape
6. 1.6 Forecast Sensitivities and Risk Framework
7. 1.7 Strategic Conclusion
Industry Overview & Forecast
1. 2.1 Market Definition and Scope
2. 2.2 Headline Market Sizing and Forecast
3. 2.3 Market Composition by Segment Category
4. 2.4 Structural Growth Drivers
5. 2.5 Segmentation by Drug Type
6. 2.6 Volume Analysis
7. 2.7 Segmentation by Therapy Area
8. 2.8 Regional Forecast
9. 2.9 Competitive Landscape and Market Concentration
10. 2.10 Forecast Sensitivities and Scenario Parameters
Market Segmentation by Type
1. 3.1 Overview and Segmentation Framework
2. 3.2 Small Molecule (Chemical)
3. 3.3 Biologics (Monoclonal Antibodies and Recombinant Proteins)
4. 3.4 Vaccines
5. 3.5 Cell and Gene Therapy
6. 3.6 Peptide Therapeutics
7. 3.7 Oligonucleotides (siRNA and Antisense Oligonucleotides)
8. 3.8 Combination, OTC and Other
9. 3.9 Volume Analysis
10. 3.10 Segment Synthesis and Competitive Implications
Market Segmentation by Application
1. 4.1 Overview and Methodology
2. 4.2 Oncology
3. 4.3 Cardio-Metabolic (Diabetes, Obesity, and Cardiovascular)
4. 4.4 Immunology and Inflammation
5. 4.5 Infectious Disease (Including Vaccines)
6. 4.6 Neurology and Central Nervous System
7. 4.7 Respiratory
8. 4.8 Rare Diseases and Orphan Drugs
9. 4.9 Other Applications
10. 4.10 Comparative Segment Analysis and Share Dynamics
Regional Market Forecast
1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East & Africa
Country-Level Market Forecast
1. 6.1 North America
2. 6.1.1 United States
3. 6.1.2 Canada
4. 6.1.3 Rest of North America
5. 6.2 Europe
6. 6.2.1 Germany
7. 6.2.2 France
8. 6.2.3 United Kingdom
9. 6.2.4 Italy
10. 6.2.5 Spain
11. 6.2.6 Russia
12. 6.2.7 Switzerland
13. 6.2.8 Netherlands
14. 6.2.9 Belgium
15. 6.2.10 Turkey
16. 6.2.11 Rest of Europe
17. 6.3 Asia-Pacific
18. 6.4 Latin America
19. 6.5 Middle East & Africa
Growth Drivers & Inhibitors
1. 7.1 Growth Drivers
2. 7.2 Market Inhibitors
3. 7.3 Integrated Assessment
Key Company Profiles
1. 8.1 Johnson & Johnson
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Pfizer
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Roche (Pharma Div.)
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Merck & Co. (MSD)
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 AbbVie
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 Business Strategy
34. 8.5.5 SWOT Analysis
35. 8.5.6 Strategic Implications (2025–2031)
36. 8.6 Novartis
37. 8.6.1 Company Overview
38. 8.6.2 Key Products & Segments
39. 8.6.3 Financial Performance (2023–2025)
40. 8.6.4 Business Strategy
41. 8.6.5 SWOT Analysis
42. 8.6.6 Strategic Implications (2025–2031)
43. 8.7 AstraZeneca
44. 8.7.1 Company Overview
45. 8.7.2 Key Products & Segments
46. 8.7.3 Financial Performance (2023–2025)
47. 8.7.4 Business Strategy
48. 8.7.5 SWOT Analysis
49. 8.7.6 Strategic Implications (2025–2031)
50. 8.8 Sanofi
51. 8.8.1 Company Overview
52. 8.8.2 Key Products & Segments
53. 8.8.3 Financial Performance (2023–2025)
54. 8.8.4 Business Strategy
55. 8.8.5 SWOT Analysis
56. 8.8.6 Strategic Implications (2025–2031)
57. 8.9 Bristol-Myers Squibb
58. 8.9.1 Company Overview
59. 8.9.2 Key Products & Segments
60. 8.9.3 Financial Performance (2023–2025)
61. 8.9.4 Business Strategy
62. 8.9.5 SWOT Analysis
63. 8.9.6 Strategic Implications (2025–2031)
64. 8.10 Eli Lilly
65. 8.10.1 Company Overview
66. 8.10.2 Key Products & Segments
67. 8.10.3 Financial Performance (2023–2025)
68. 8.10.4 Business Strategy
69. 8.10.5 SWOT Analysis
70. 8.10.6 Strategic Implications (2025–2031)
71. 8.11 GSK
72. 8.11.1 Company Overview
73. 8.11.2 Key Products & Segments
74. 8.11.3 Financial Performance (2023–2025)
75. 8.11.4 Business Strategy
76. 8.11.5 SWOT Analysis
77. 8.11.6 Strategic Implications (2025–2031)
78. 8.12 Novo Nordisk
79. 8.12.1 Company Overview
80. 8.12.2 Key Products & Segments
81. 8.12.3 Financial Performance (2023–2025)
82. 8.12.4 Business Strategy
83. 8.12.5 SWOT Analysis
84. 8.12.6 Strategic Implications (2025–2031)
85. 8.13 Takeda
86. 8.13.1 Company Overview
87. 8.13.2 Key Products & Segments
88. 8.13.3 Financial Performance (2023–2025)
89. 8.13.4 Business Strategy
90. 8.13.5 SWOT Analysis
91. 8.13.6 Strategic Implications (2025–2031)
92. 8.14 Bayer (Pharma Div.)
93. 8.14.1 Company Overview
94. 8.14.2 Key Products & Segments
95. 8.14.3 Financial Performance (2023–2025)
96. 8.14.4 Business Strategy
97. 8.14.5 SWOT Analysis
98. 8.14.6 Strategic Implications (2025–2031)
99. 8.15 Boehringer Ingelheim
100. 8.15.1 Company Overview
101. 8.15.2 Key Products & Segments
102. 8.15.3 Financial Performance (2023–2025)
103. 8.15.4 Business Strategy
104. 8.15.5 SWOT Analysis
105. 8.15.6 Strategic Implications (2025–2031)
106. 8.16 Amgen
107. 8.16.1 Company Overview
108. 8.16.2 Key Products & Segments
109. 8.16.3 Financial Performance (2023–2025)
110. 8.16.4 Business Strategy
111. 8.16.5 SWOT Analysis
112. 8.16.6 Strategic Implications (2025–2031)
113. 8.17 Gilead Sciences
114. 8.17.1 Company Overview
115. 8.17.2 Key Products & Segments
116. 8.17.3 Financial Performance (2023–2025)
117. 8.17.4 Business Strategy
118. 8.17.5 SWOT Analysis
119. 8.17.6 Strategic Implications (2025–2031)
120. 8.18 Vertex Pharma
121. 8.18.1 Company Overview
122. 8.18.2 Key Products & Segments
123. 8.18.3 Financial Performance (2023–2025)
124. 8.18.4 Business Strategy
125. 8.18.5 SWOT Analysis
126. 8.18.6 Strategic Implications (2025–2031)
127. 8.19 Regeneron
128. 8.19.1 Company Overview
129. 8.19.2 Key Products & Segments
130. 8.19.3 Financial Performance (2023–2025)
131. 8.19.4 Business Strategy
132. 8.19.5 SWOT Analysis
133. 8.19.6 Strategic Implications (2025–2031)
134. 8.20 Biogen
135. 8.20.1 Company Overview
136. 8.20.2 Key Products & Segments
137. 8.20.3 Financial Performance (2023–2025)
138. 8.20.4 Business Strategy
139. 8.20.5 SWOT Analysis
140. 8.20.6 Strategic Implications (2025–2031)
141. 8.21 Moderna
142. 8.21.1 Company Overview
143. 8.21.2 Key Products & Segments
144. 8.21.3 Financial Performance (2023–2025)
145. 8.21.4 Business Strategy
146. 8.21.5 SWOT Analysis
147. 8.21.6 Strategic Implications (2025–2031)
148. 8.22 Teva Pharma
149. 8.22.1 Company Overview
150. 8.22.2 Key Products & Segments
151. 8.22.3 Financial Performance (2023–2025)
152. 8.22.4 Business Strategy
153. 8.22.5 SWOT Analysis
154. 8.22.6 Strategic Implications (2025–2031)
155. 8.23 Viatris
156. 8.23.1 Company Overview
157. 8.23.2 Key Products & Segments
158. 8.23.3 Financial Performance (2023–2025)
159. 8.23.4 Business Strategy
160. 8.23.5 SWOT Analysis
161. 8.23.6 Strategic Implications (2025–2031)
162. 8.24 Sun Pharma
163. 8.24.1 Company Overview
164. 8.24.2 Key Products & Segments
165. 8.24.3 Financial Performance (2023–2025)
166. 8.24.4 Business Strategy
167. 8.24.5 SWOT Analysis
168. 8.24.6 Strategic Implications (2025–2031)
169. 8.25 Dr. Reddy's Labs
170. 8.25.1 Company Overview
171. 8.25.2 Key Products & Segments
172. 8.25.3 Financial Performance (2023–2025)
173. 8.25.4 Business Strategy
174. 8.25.5 SWOT Analysis
175. 8.25.6 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.2 Competitive Intensity Assessment
3. 9.3 Key Player Strategies & Positioning
4. 9.4 Competitive Dynamics & Strategic Outlook
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Political
2. 11.2 Economic
3. 11.3 Social
4. 11.4 Technological
5. 11.5 Legal
6. 11.6 Environmental
SWOT Analysis
1. 12.1 Strengths
2. 12.2 Weaknesses
3. 12.3 Opportunities
4. 12.4 Threats
Future Trends & Outlook
1. 13.1 Structural Context
2. 13.2 Key Trends
3. 13.3 Strategic Outlook

List of Exhibits

Exhibit 2.1: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
Exhibit 2.2: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
Exhibit 2.3: Forecast of North America (in USD Bn)
Exhibit 2.4: Forecast of North America (in bsu)
Exhibit 2.5: Forecast of Europe (in USD Bn)
Exhibit 2.6: Forecast of Europe (in bsu)
Exhibit 2.7: Forecast of Asia-Pacific (in USD Bn)
Exhibit 2.8: Forecast of Asia-Pacific (in bsu)
Exhibit 2.9: Forecast of Latin America (in USD Bn)
Exhibit 2.10: Forecast of Latin America (in bsu)
Exhibit 2.11: Forecast of Middle East & Africa (in USD Bn)
Exhibit 2.12: Forecast of Middle East & Africa (in bsu)
Exhibit 2.13: Forecast of Global (in USD Bn)
Exhibit 2.14: Forecast of Global (in bsu)
Exhibit 3.15: Forecast of Small Molecule (Chemical) (in USD Bn)
Exhibit 3.16: Forecast of Small Molecule (Chemical) (in bsu)
Exhibit 3.17: Forecast of Biologics (mAbs, Recombinant Proteins) (in USD Bn)
Exhibit 3.18: Forecast of Biologics (mAbs, Recombinant Proteins) (in bsu)
Exhibit 3.19: Forecast of Vaccines (in USD Bn)
Exhibit 3.20: Forecast of Vaccines (in bsu)
Exhibit 3.21: Forecast of Cell & Gene Therapy (in USD Bn)
Exhibit 3.22: Forecast of Cell & Gene Therapy (in bsu)
Exhibit 3.23: Forecast of Peptide Therapeutics (in USD Bn)
Exhibit 3.24: Forecast of Peptide Therapeutics (in bsu)
Exhibit 3.25: Forecast of Oligonucleotides (siRNA, ASO) (in USD Bn)
Exhibit 3.26: Forecast of Oligonucleotides (siRNA, ASO) (in bsu)
Exhibit 3.27: Forecast of Combination, OTC & Other (in USD Bn)
Exhibit 3.28: Forecast of Combination, OTC & Other (in bsu)
Exhibit 4.29: Forecast of Oncology (in USD Bn)
Exhibit 4.30: Forecast of Oncology (in bsu)
Exhibit 4.31: Forecast of Cardio-Metabolic (Diab/Obesity/CV) (in USD Bn)
Exhibit 4.32: Forecast of Cardio-Metabolic (Diab/Obesity/CV) (in bsu)
Exhibit 4.33: Forecast of Immunology / Inflammation (in USD Bn)
Exhibit 4.34: Forecast of Immunology / Inflammation (in bsu)
Exhibit 4.35: Forecast of Infectious Disease (incl. Vaccines) (in USD Bn)
Exhibit 4.36: Forecast of Infectious Disease (incl. Vaccines) (in bsu)
Exhibit 4.37: Forecast of Neurology / CNS (in USD Bn)
Exhibit 4.38: Forecast of Neurology / CNS (in bsu)
Exhibit 4.39: Forecast of Respiratory (in USD Bn)
Exhibit 4.40: Forecast of Respiratory (in bsu)
Exhibit 4.41: Forecast of Rare Diseases / Orphan (in USD Bn)
Exhibit 4.42: Forecast of Rare Diseases / Orphan (in bsu)
Exhibit 4.43: Forecast of Other (Ophth, Derm, Women's, GI, Pain) (in USD Bn)
Exhibit 4.44: Forecast of Other (Ophth, Derm, Women's, GI, Pain) (in bsu)
Exhibit 6.45: Forecast of North America (in USD Bn)
Exhibit 6.46: Forecast of United States (in USD Bn)
Exhibit 6.47: Forecast of Canada (in USD Bn)
Exhibit 6.48: Forecast of Rest of North America (in USD Bn)
Exhibit 6.49: Forecast of North America (in bsu)
Exhibit 6.50: Forecast of United States (in bsu)
Exhibit 6.51: Forecast of Canada (in bsu)
Exhibit 6.52: Forecast of Rest of North America (in bsu)
Exhibit 6.53: Forecast of Europe (in USD Bn)
Exhibit 6.54: Forecast of Germany (in USD Bn)
Exhibit 6.55: Forecast of France (in USD Bn)
Exhibit 6.56: Forecast of United Kingdom (in USD Bn)
Exhibit 6.57: Forecast of Italy (in USD Bn)
Exhibit 6.58: Forecast of Spain (in USD Bn)
Exhibit 6.59: Forecast of Russia (in USD Bn)
Exhibit 6.60: Forecast of Switzerland (in USD Bn)
Exhibit 6.61: Forecast of Netherlands (in USD Bn)
Exhibit 6.62: Forecast of Belgium (in USD Bn)
Exhibit 6.63: Forecast of Turkey (in USD Bn)
Exhibit 6.64: Forecast of Rest of Europe (in USD Bn)
Exhibit 6.65: Forecast of Europe (in bsu)
Exhibit 6.66: Forecast of Germany (in bsu)
Exhibit 6.67: Forecast of France (in bsu)
Exhibit 6.68: Forecast of United Kingdom (in bsu)
Exhibit 6.69: Forecast of Italy (in bsu)
Exhibit 6.70: Forecast of Spain (in bsu)
Exhibit 6.71: Forecast of Russia (in bsu)
Exhibit 6.72: Forecast of Switzerland (in bsu)
Exhibit 6.73: Forecast of Netherlands (in bsu)
Exhibit 6.74: Forecast of Belgium (in bsu)
Exhibit 6.75: Forecast of Turkey (in bsu)
Exhibit 6.76: Forecast of Rest of Europe (in bsu)
Exhibit 6.77: Forecast of Asia-Pacific (in USD Bn)
Exhibit 6.78: Forecast of China (in USD Bn)
Exhibit 6.79: Forecast of Japan (in USD Bn)
Exhibit 6.80: Forecast of India (in USD Bn)
Exhibit 6.81: Forecast of South Korea (in USD Bn)
Exhibit 6.82: Forecast of Australia (in USD Bn)
Exhibit 6.83: Forecast of Rest of Asia Pacific (in USD Bn)
Exhibit 6.84: Forecast of Asia-Pacific (in bsu)
Exhibit 6.85: Forecast of China (in bsu)
Exhibit 6.86: Forecast of Japan (in bsu)
Exhibit 6.87: Forecast of India (in bsu)
Exhibit 6.88: Forecast of South Korea (in bsu)
Exhibit 6.89: Forecast of Australia (in bsu)
Exhibit 6.90: Forecast of Rest of Asia Pacific (in bsu)
Exhibit 6.91: Forecast of Latin America (in USD Bn)
Exhibit 6.92: Forecast of Brazil (in USD Bn)
Exhibit 6.93: Forecast of Mexico (in USD Bn)
Exhibit 6.94: Forecast of Rest of Latin America (in USD Bn)
Exhibit 6.95: Forecast of Latin America (in bsu)
Exhibit 6.96: Forecast of Brazil (in bsu)
Exhibit 6.97: Forecast of Mexico (in bsu)
Exhibit 6.98: Forecast of Rest of Latin America (in bsu)
Exhibit 6.99: Forecast of Middle East & Africa (in USD Bn)
Exhibit 6.100: Forecast of Saudi Arabia (in USD Bn)
Exhibit 6.101: Forecast of United Arab Emirates (in USD Bn)
Exhibit 6.102: Forecast of South Africa (in USD Bn)
Exhibit 6.103: Forecast of Rest of MEA (in USD Bn)
Exhibit 6.104: Forecast of Middle East & Africa (in bsu)
Exhibit 6.105: Forecast of Saudi Arabia (in bsu)
Exhibit 6.106: Forecast of United Arab Emirates (in bsu)
Exhibit 6.107: Forecast of South Africa (in bsu)
Exhibit 6.108: Forecast of Rest of MEA (in bsu)

Companies Covered

Johnson & Johnson, Pfizer, Roche, Merck & Co. (MSD), AbbVie, Novartis, AstraZeneca, Sanofi, Bristol-Myers Squibb, Eli Lilly, GSK, Novo Nordisk, Takeda, Bayer, Boehringer Ingelheim, Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron, Biogen, Moderna, Teva, Viatris, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Buying Frequently for your Organization?

Need Custom Market Research Solution?

Tabs

Segment by Type in Global Pharmaceuticals Industry Market

Segment by Application in Global Pharmaceuticals Industry Market

Segment by Region in Global Pharmaceuticals Industry Market

Who can use the Global Pharmaceuticals Industry Market Research Report?

Single User License (PDF)

Site License (PDF)*

Enterprise License (PDF)*

Latest Market Research Reports

Global GLP-1 Drug Manufacturing & Supply

Global Oncology Market Strategic Research Report

Global Perlite and Vermiculite Market Strategic

Global GLP-1 Drug Market Strategic Research

Global Pharmaceuticals Industry Strategic

Global Pharmaceuticals Market Strategic

About Us

Infomation